Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Trial Profile

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 5878 (Primary)
  • Indications Bladder cancer; Breast cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Apr 2019 Results published in the Investigational New Drugs Journal.
    • 12 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top